681 related articles for article (PubMed ID: 29146095)
1. A two-year study using cerebral gray matter volume to assess the response to fingolimod therapy in multiple sclerosis.
Yousuf F; Dupuy SL; Tauhid S; Chu R; Kim G; Tummala S; Khalid F; Weiner HL; Chitnis T; Healy BC; Bakshi R
J Neurol Sci; 2017 Dec; 383():221-229. PubMed ID: 29146095
[TBL] [Abstract][Full Text] [Related]
2. Exploring the effect of glatiramer acetate on cerebral gray matter atrophy in multiple sclerosis.
AbdelRazek MA; Tummala S; Khalid F; Tauhid S; Jalkh Y; Khalil S; Hurwitz S; Zurawski J; Bakshi R
J Neurol Sci; 2023 Jan; 444():120501. PubMed ID: 36481574
[TBL] [Abstract][Full Text] [Related]
3. Two-year regional grey and white matter volume changes with natalizumab and fingolimod.
Preziosa P; Rocca MA; Pagani E; Storelli L; Rodegher M; Moiola L; Filippi M
J Neurol Neurosurg Psychiatry; 2020 May; 91(5):493-502. PubMed ID: 32111638
[TBL] [Abstract][Full Text] [Related]
4. A longitudinal uncontrolled study of cerebral gray matter volume in patients receiving natalizumab for multiple sclerosis.
Khalid F; Tauhid S; Chua AS; Healy BC; Stankiewicz JM; Weiner HL; Bakshi R
Int J Neurosci; 2017 May; 127(5):396-403. PubMed ID: 27143245
[TBL] [Abstract][Full Text] [Related]
5. Fingolimod effect on gray matter, thalamus, and white matter in patients with multiple sclerosis.
Gaetano L; Häring DA; Radue EW; Mueller-Lenke N; Thakur A; Tomic D; Kappos L; Sprenger T
Neurology; 2018 Apr; 90(15):e1324-e1332. PubMed ID: 29540589
[TBL] [Abstract][Full Text] [Related]
6. Quantitative MRI analysis of cerebral lesions and atrophy in post-partum patients with multiple sclerosis.
Khalid F; Healy BC; Dupuy SL; Chu R; Chitnis T; Bakshi R; Houtchens M
J Neurol Sci; 2018 Sep; 392():94-99. PubMed ID: 30031994
[TBL] [Abstract][Full Text] [Related]
7. Fingolimod's Impact on MRI Brain Volume Measures in Multiple Sclerosis: Results from MS-MRIUS.
Zivadinov R; Medin J; Khan N; Korn JR; Bergsland N; Dwyer MG; Chitnis T; Naismith RT; Alvarez E; Kinkel P; Cohan S; Hunter SF; Silva D; Weinstock-Guttman B;
J Neuroimaging; 2018 Jul; 28(4):399-405. PubMed ID: 29749661
[TBL] [Abstract][Full Text] [Related]
8. Deep gray matter volume loss drives disability worsening in multiple sclerosis.
Eshaghi A; Prados F; Brownlee WJ; Altmann DR; Tur C; Cardoso MJ; De Angelis F; van de Pavert SH; Cawley N; De Stefano N; Stromillo ML; Battaglini M; Ruggieri S; Gasperini C; Filippi M; Rocca MA; Rovira A; Sastre-Garriga J; Vrenken H; Leurs CE; Killestein J; Pirpamer L; Enzinger C; Ourselin S; Wheeler-Kingshott CAMG; Chard D; Thompson AJ; Alexander DC; Barkhof F; Ciccarelli O;
Ann Neurol; 2018 Feb; 83(2):210-222. PubMed ID: 29331092
[TBL] [Abstract][Full Text] [Related]
9. Whole brain and deep gray matter atrophy detection over 5 years with 3T MRI in multiple sclerosis using a variety of automated segmentation pipelines.
Chu R; Kim G; Tauhid S; Khalid F; Healy BC; Bakshi R
PLoS One; 2018; 13(11):e0206939. PubMed ID: 30408094
[TBL] [Abstract][Full Text] [Related]
10. The Effect of Fingolimod on Conversion of Acute Gadolinium-Enhancing Lesions to Chronic T1 Hypointensities in Multiple Sclerosis.
Oommen VV; Tauhid S; Healy BC; Chua AS; Malik MT; Diaz-Cruz C; Dupuy SL; Weiner HL; Chitnis T; Bakshi R
J Neuroimaging; 2016; 26(2):184-7. PubMed ID: 26445919
[TBL] [Abstract][Full Text] [Related]
11. MRI phenotypes based on cerebral lesions and atrophy in patients with multiple sclerosis.
Tauhid S; Neema M; Healy BC; Weiner HL; Bakshi R
J Neurol Sci; 2014 Nov; 346(1-2):250-4. PubMed ID: 25220114
[TBL] [Abstract][Full Text] [Related]
12. The effect of fingolimod on focal and diffuse grey matter damage in active MS patients.
Bajrami A; Pitteri M; Castellaro M; Pizzini F; Romualdi C; Montemezzi S; Monaco S; Calabrese M
J Neurol; 2018 Sep; 265(9):2154-2161. PubMed ID: 29938336
[TBL] [Abstract][Full Text] [Related]
13. Effect of glatiramer acetate on cerebral grey matter pathology in patients with relapsing-remitting multiple sclerosis.
Crescenzo F; Marastoni D; Zuco C; Pitteri M; Magliozzi R; Monaco S; Calabrese M
Mult Scler Relat Disord; 2019 Jan; 27():305-311. PubMed ID: 30453199
[TBL] [Abstract][Full Text] [Related]
14. Effect of fingolimod on diffuse brain tissue damage in relapsing-remitting multiple sclerosis patients.
De Stefano N; Tomic D; Radue EW; Sprenger T; Meier DP; Häring D; Sormani MP
Mult Scler Relat Disord; 2016 May; 7():98-101. PubMed ID: 27237768
[TBL] [Abstract][Full Text] [Related]
15. Effects of Natalizumab and Fingolimod on Clinical, Cognitive, and Magnetic Resonance Imaging Measures in Multiple Sclerosis.
Preziosa P; Rocca MA; Riccitelli GC; Moiola L; Storelli L; Rodegher M; Comi G; Signori A; Falini A; Filippi M
Neurotherapeutics; 2020 Jan; 17(1):208-217. PubMed ID: 31452082
[TBL] [Abstract][Full Text] [Related]
16. Multimodal MRI Response to Fingolimod in Multiple Sclerosis: A Nonrandomized, Single Arm, Observational Study.
Bernitsas E; Kopinsky H; Lichtman-Mikol S; Razmjou S; Santiago-Martinez C; Yarraguntla K; Bao F
J Neuroimaging; 2021 Mar; 31(2):379-387. PubMed ID: 33368776
[TBL] [Abstract][Full Text] [Related]
17. Effect of intramuscular interferon beta-1a on gray matter atrophy in relapsing-remitting multiple sclerosis: A retrospective analysis.
Fisher E; Nakamura K; Lee JC; You X; Sperling B; Rudick RA
Mult Scler; 2016 Apr; 22(5):668-76. PubMed ID: 26238463
[TBL] [Abstract][Full Text] [Related]
18. Grey matter atrophy is associated with disability increase in natalizumab-treated patients.
Ciampi E; Pareto D; Sastre-Garriga J; Vidal-Jordana A; Tur C; Río J; Tintoré M; Auger C; Rovira A; Montalban X
Mult Scler; 2017 Apr; 23(4):556-566. PubMed ID: 27354019
[TBL] [Abstract][Full Text] [Related]
19. Regional gray matter atrophy in relapsing remitting multiple sclerosis: baseline analysis of multi-center data.
Datta S; Staewen TD; Cofield SS; Cutter GR; Lublin FD; Wolinsky JS; Narayana PA; ;
Mult Scler Relat Disord; 2015 Mar; 4(2):124-36. PubMed ID: 25787188
[TBL] [Abstract][Full Text] [Related]
20. Sample size requirements for one-year treatment effects using deep gray matter volume from 3T MRI in progressive forms of multiple sclerosis.
Kim G; Chu R; Yousuf F; Tauhid S; Stazzone L; Houtchens MK; Stankiewicz JM; Severson C; Kimbrough D; Quintana FJ; Chitnis T; Weiner HL; Healy BC; Bakshi R
Int J Neurosci; 2017 Nov; 127(11):971-980. PubMed ID: 28100092
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
